Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat fibrotic diseases. Fibrosis is a process that occurs in many diseases, when normal healthy tissue is replaced with scar tissue, compromising normal function and leading ultimately to organ failure. Promedior's proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that acts through a unique anti-fibrotic immunotherapy mechanism to activate a regulatory switch upstream in the fibrosis cascade.
Promedior has built a strong team experienced in developing, advancing, and commercializing products for a wide range of disorders including orphan diseases. The company has successfully advanced its lead therapeutic candidate into Phase 2 human clinical trials. Promedior is supported by leading global healthcare venture investors and has secured important intellectual property relating to the pioneering discoveries and applications of the company's therapeutics.
Proprietary platform: Promedior's drug candidates are based on Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. Normal wound healing involves the inflammation, proliferation, and resolution pathways. Fibrosis occurs when the normal wound healing response gets locked into the proliferation pathway, resulting in dysregulated scar tissue formation and, ultimately, organ dysfunction and potentially death.
Pentraxin-2 is a naturally occurring protein that directs the immune system to simultaneously turn off the fibrosis pathway and turn on a resolution pathway, specifically in areas of tissue injury. Other therapeutic approaches in development typically focus on inhibiting single targets far downstream in the fibrosis cascade, many of which are redundant and thus difficult to effectively block. Pentraxin-2 works as an upstream agonist, potentially halting further progression of fibrotic disease and promoting beneficial healing.
Clinical advancements: Promedior has successfully advanced its lead therapeutic candidate in human clinical trials. The company's lead product, PRM-151, is currently being studied in a Phase 2 clinical trial in myelofibrosis (MF) patients, with interim data announced at the American Society of Clinical Oncology (ASCO) meeting in June 2014 and at the American Society of Hematology (ASH) meetings in 2014 and 2015, which included data from patients that have been treated with PRM-151 for 72 weeks. A new phase 2 trial in myelofibrosis is currently enrolling. PRM-151 has completed a Phase 1b clinical study in idiopathic pulmonary fibrosis (IPF) patients, and these data were presented at the American Thoracic Society meeting in May, 2013. In an earlier Phase 1a study, PRM-151 was generally safe and well tolerated. A new phase 2 study in IPF is also currently enrolling. Additionally, PRM-151 demonstrated robust efficacy in multiple preclinical models of fibrotic disease, including reductions in established fibrosis and improvement in organ function.
Strategic focus: Promedior is initially focused on rare fibrotic diseases, such as myelofibrosis and IPF, and retinal fibrovascular diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR).
Crystal structure of human Pentraxin-2, a naturally occurring protein that is the foundation of Promedior's proprietary platform. Learn More >
Based on the broad potential of its Pentraxin-2 platform, Promedior is developing a pipeline of potential therapies. Learn More >